No immediate catalyst. Monitor for any future equity issuances under the new plan or authorized share increase, which could dilute existing holders. The doubling of authorized shares provides flexibility but signals no near-term capital need.
SPRO drugs
SPRO drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jun 26 $2.26entry
- T+1 · 5mo ago 0.00%α −1.65% · $2.26
- T+5 · 4mo ago −2.65%α −4.82% · $2.20
- T+20 · 4mo ago −48.67%α −49.93% · $1.16
- T+60 · 8w ago −49.56%α −55.66% · $1.14
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Spero Therapeutics filed an 8-K reporting shareholder approval to double authorized common shares from 120M to 240M and adopt a new 2026 Stock Incentive Plan authorizing up to 12.9M shares. These are routine post-annual-meeting governance actions with no immediate financial impact or operational changes.
Key Facts
- Shareholders approved amendment to increase authorized common shares from 120,000,000 to 240,000,000.
- Shareholders approved the 2026 Stock Incentive Plan, authorizing up to 12,895,866 shares for issuance.
- Annual meeting held June 23, 2026; quorum of 70.91% of outstanding shares present.
- Directors Milind Deshpande and Kathleen Tregoning were reelected as Class III directors.
- PricewaterhouseCoopers LLP ratified as independent auditor for fiscal 2026.
Financial Impact
No immediate financial impact; potential future dilution from up to 12.9M new shares under the equity plan, but no current issuance.
Risk Factors
- Potential dilution if the company issues shares under the new incentive plan or authorized increase.
- No operational or financial updates in this filing; stock may drift on lack of news.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-283033 |
| Document: d86736dex31.htm | 0001193125-26-283033 |
| Document: 0001193125-26-283033-index-headers.html | 0001193125-26-283033 |
| Document: 0001193125-26-283033-index.html | 0001193125-26-283033 |
| Document: 0001193125-26-283033.txt | 0001193125-26-283033 |
Track record
17 reports on SPRO
4 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.59% at T+20 after the Mar 26, 2026 report. 5 of 8 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $0.9999 Now $0.9460 −5.39% settles Nov 20
- Nov 10, 20266d ago 3 Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Nov 10, 20266d ago 8-K Neutral 2/10 Entry $1.02 Now $0.9460 −7.25% settles Nov 18
- Oct 27, 202620d ago 8-K Neutral 2/10 Entry $1.17 to $1.07 Now $0.9460 −19.15% ▼ −8.55% −7.83% vs SPY
- Sep 11, 20269w ago EFFECT Bearish 7/10 Entry $1.13 to $1.13 Now $0.9460 +16.28% · 0.00% −0.34% vs SPY
- Aug 28, 202611w ago 8-K Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 28, 202611w ago S-3 Bearish 7/10 Entry $1.22 to $1.19 Now $0.9460 +22.46% ▲ +2.46% +2.32% vs SPY
- Aug 12, 202613w ago Press Release Neutral 4/10 Entry $1.24 to $1.22 Now $0.9460 −23.71% ▼ −1.61% +0.35% vs SPY
- Jul 14, 202617w ago 8-K Bullish 8/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
- Jul 14, 202617w ago Press Release Bullish 7/10 Entry $1.70 to $1.44 Now $0.9460 −44.35% ▼ −15.29% −14.00% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers